KR20130042726A - Pharmaceutical composition for treatment of tonsilitis containing selaginella tamariscina spring extracts or fractions thereof - Google Patents

Abstract

PURPOSE: A pharmaceutical composition containing a Selaginella tamariscina extract or a fraction thereof for preventing or treating tonsillitis is provided to ensure antibacterial activity against hemolytic Streptococcus and Staphylococcus. CONSTITUTION: A pharmaceutical composition for preventing or treating tonsillitis contains a Selaginella tamariscina extract or a fraction thereof and a pharmaceutically acceptable carrier. The extract is prepared using water, C1-C4 alcohol, or a mixture solvent thereof. The C1-C4 alcohol is methanol or ethanol. The fraction is prepared by fractioning the extract with an organic solvent. The organic solvent is hexane, chloroform, methylene chloride, ethyl acetate, or butanol. The pharmaceutical composition contains 0.02-50 wt% of the extract or the fraction. [Reference numerals] (AA) Size of a transparent zone(mm); (BB) Example 1; (CC) Example 2; (DD) Methicillin; (EE) Penicillin;

Description

PHARMACEUTICAL COMPOSITION FOR TREATMENT OF TONSILITIS CONTAINING SELAGINELLA TAMARISCINA SPRING EXTRACTS OR FRACTIONS THEREOF}

The present invention relates to a pharmaceutical composition for the prevention or treatment of tonsillitis, and more particularly to a pharmaceutical composition for the prevention or treatment of tonsillitis, which comprises Buddha extract or fractions thereof as an active ingredient.

Tonsillitis is inflammation of the palatal tonsil, which consists of the tonsils, pharyngeal tonsils, and palate tonsills, and can be classified as acute or chronic tonsillitis. Most of them are caused by bacterial or viral infections. The most common pathogens are β-hemolytic streptococci, and staphylococci, pneumococci, Haemophilus and various anaerobic strains may also be the causative agents. Viruses are also a common causative agent of acute tonsillitis, including influenza virus, parainfluenza virus, herpes simplex virus, coxsackievirus, and echovirus. , Rhinovirus, respiratory syncytial virus, and the like. The preceding factors are known as fatigue, exposure to low or high temperatures, upper respiratory tract infections, metabolic diseases and immune diseases.

If symptoms of tonsillitis persist, it can lead to peritonsilitis, cervical and deep infections, and sepsis. In addition, swelling around the tonsils due to inflammation may cause airway obstruction, and infection may spread to distant organs such as lung, brain, and heart, so it is important to treat early.

Treatment of tonsillitis can be divided into surgical and non-surgical treatment. Surgical treatment is performed for recurrent tonsillitis, and the tonsil is removed through surgery. Non-surgical treatment is an appropriate conservative treatment to remove inflammation and relieve symptoms. It is possible to treat tonsillitis by administering various chemical drugs such as aspirin or antibiotics such as mycin and penicillin. have. These non-surgical treatments are put in a variety of drugs, there is a risk of abuse of chemical drugs, antibiotics are rather resistant and do not respond well to slow the therapeutic effect. Therefore, in recent years, interest in the treatment of tonsillitis using natural extracts or fractions thereof is increasing.

On the other hand, Selaginella tamariscina Spring is an evergreen perennial herb that grows in stone gaps in Jeju Island, Ulleungdo, South, Central, and North Korea. It is about 20cm tall and leaves are 1.5 ~ 2㎜ long. It is a projection and is densely arranged in 4 lines and ovate. The branches are split into planes, the surface is dark green, and the back side is white green. Branches spread in all directions when wet, and curled into balls when dry, and spread again when there is moisture. Spores are 0.5 ~ 1.5㎝ long, 2㎜ in diameter, one at the end of twigs, square. It is used for ornamental purposes, and leaves, stems, and roots are used for medicinal purposes.

As a result, the treatment or prevention of tonsillitis has become an important problem, and the use of Buddha hands as such therapeutic agents has been of interest.

The present invention has been proposed to solve the above problems of the conventionally proposed methods, by including the Buddha extract or a fraction thereof as an active ingredient, to provide a pharmaceutical composition for the prevention or treatment of tonsillitis, which can prevent or treat tonsillitis. It is for that purpose.

According to a feature of the present invention for achieving the above object, tonsillitis prevention or treatment pharmaceutical composition

Budsonson extract or fractions thereof; And

It is characterized by its configuration as including a pharmaceutically acceptable carrier.

Preferably, the Buddha hand extract,

Extraction may be performed using water, C1 to C4 lower alcohols, or a mixed solvent thereof.

More preferably, the lower alcohol of C1 to C4,

Methanol or ethanol.

Preferably, the fraction is,

The Buddha extract can be fractionated using an organic solvent.

More preferably, the organic solvent,

Hexane, chloroform, methylene chloride, ethyl acetate or butanol.

Preferably, the pharmaceutical composition,

With respect to the total weight of the pharmaceutical composition may include the Buddha extract or the fraction of the Buddha extract as 0.02 to 50% by weight.

According to the pharmaceutical composition for the prevention or treatment of tonsillitis proposed by the present invention, by including the Buddha extract or fractions thereof as an active ingredient, it is possible to prevent or treat tonsillitis by showing antibacterial activity of hemolytic streptococci, staphylococci, and the like.

1 is a view showing the antimicrobial activity test results of Buddha extract or fraction thereof as an active ingredient in a pharmaceutical composition for preventing or treating tonsillitis according to an embodiment of the present invention.

Hereinafter, preferred embodiments of the present invention will be described in detail with reference to the accompanying drawings, in order that those skilled in the art can easily carry out the present invention. In the following detailed description of the preferred embodiments of the present invention, a detailed description of known functions and configurations incorporated herein will be omitted when it may make the subject matter of the present invention rather unclear. In the drawings, like reference numerals are used throughout the drawings.

In addition, in the entire specification, when a part is referred to as being 'connected' to another part, it may be referred to as 'indirectly connected' not only with 'directly connected' . In addition, the term 'comprising' of an element means that the element may further include other elements, not to exclude other elements unless specifically stated otherwise.

Pharmaceutical composition for the prevention or treatment of tonsillitis according to an embodiment of the present invention is characterized by comprising the Buddha extract or a fraction thereof as an active ingredient. More specifically, the Butcherson extract can be extracted using water, lower alcohols of C1 to C4, or a mixed solvent thereof, and the fraction can be obtained by adding an organic solvent to the Butcherson extract. In addition, the content of the Buddha extract or fractions thereof contained in the pharmaceutical composition for the prevention or treatment of tonsillitis according to an embodiment of the present invention, it is preferably included in 0.02 to 50% by weight relative to the total weight% of the pharmaceutical composition. When included in less than 0.02% by weight, almost no effect of the Buddha extract or fractions thereof, and more than 50% by weight is not only disadvantageous to the stability of the pharmaceutical composition, but also does not appear to be synergistic effect of the effect of excess addition I can't.

Hereinafter, a process of preparing the Buddha extract or a fraction thereof in the pharmaceutical composition for preventing or treating tonsillitis according to an embodiment of the present invention will be described in detail.

Butcherson extract can be extracted using water, C1 to C4 lower alcohol or a mixed solvent thereof. That is, the leaves, stems, and roots of the Buddha's hand are cut into fine pieces or ground with a crusher to fine powder, and then put into an extraction container, followed by water, a lower alcohol of C1 to C4, preferably methanol or ethanol, or their After mixing and extracting the mixed solvent, it is left for a certain time and then filtered with filter paper to obtain the Buddha hand extract. On the other hand, the method of extracting the extract from the Buddha hand can be extracted through various methods such as hot water extraction, cold needle extraction, reflux extraction, ultrasonic extraction, but is not limited thereto.

In addition, the fraction of the Buddha extract can be obtained by suspending the Buddha extract in water or distilled water and then fractionating by adding a nonpolar or polar organic solvent. Non-polar organic solvents may include hexane, chloroform, methylenechlorite or ethyl acetate, and polar organic solvents may include but are not limited to acetone, butanol, ethanol or methanol.

Meanwhile, the pharmaceutical composition for preventing or treating tonsillitis according to one embodiment of the present invention may include a pharmaceutically acceptable carrier in addition to the extract of Butcherson, which is an active ingredient, or a fraction thereof. Pharmaceutically acceptable carriers may include, but are not limited to, saline, polyethylene glycol, ethanol, vegetable oils, isopropyl myristate, and the like.

The pharmaceutical dosage form of the pharmaceutical composition for preventing or treating tonsillitis according to one embodiment of the present invention may be used in the form of their pharmaceutically acceptable salts, and may also be used alone or in combination with other pharmaceutically active compounds. Can be used as a set.

In addition, tonsillitis prevention or treatment pharmaceutical composition according to an embodiment of the present invention, may be formulated in oral dosage forms, such as powders, granules, tablets, capsules, syrups, and general saline, 5% dextrose and The Buddha extract or fractions thereof may be formulated as an injection by dissolving, suspending or emulsifying it in a water-soluble solvent or a non-aqueous solvent such as vegetable oil, synthetic fatty acid glyceride, higher fatty acid ester or propylene glycol. The pharmaceutical composition for preventing or treating tonsillitis according to one embodiment of the present invention may include conventional additives such as solubilizers, isotonic agents, suspending agents, emulsifiers, stabilizers and preservatives.

The preferred dosage of the pharmaceutical composition for preventing or treating tonsillitis according to one embodiment of the present invention depends on the condition and weight of the patient, the extent of the disease, the form of the drug, the route and duration of administration, and may be appropriately selected by those skilled in the art. have. However, preferably, the pharmaceutical composition for preventing or treating tonsillitis according to one embodiment of the present invention may be administered at 0.001-100 mg / kg body weight per day, and more preferably, 0.01-30 mg / kg body weight. can do. Administration may be administered once a day or may be divided several times.

The present invention is described in more detail by the following examples, but the present invention is not limited in any way by the following examples.

Preparation of Buddha Hand Extract

The washed Buddha hands were dried and crushed through a crusher, and the crushed Buddha hands were placed in an extraction container. Then, the mixture was immersed in 100% methanol having a volume of 5 times the weight of Buddha, extracted under reflux for 10 hours, cooled at room temperature, filtered through a filter paper, and then concentrated under reduced pressure until the solution was completely evaporated using a concentrate. 150 g) was obtained.

Of Buddha Hand Extract Fraction  Produce

The Busonson extract (150 g) obtained in Example 1 was suspended in water (1 L), and then fractionated using hexane, chloroform, ethyl acetate and butanol, and then separated into hexane (13.4 g), chloroform (25.5 g), and ethyl acetate (30 g). ), Butanol (35.5 g) and aqueous (24 g) fractions were obtained.

Hereinafter, the effects of the present invention will be described in more detail through experimental examples, but the scope of the present invention is not limited by the following experimental examples.

[ Experimental Example  1] antibacterial test

In order to confirm the antimicrobial activity of the fraction of the butcherson extract prepared in Example 1 or the butcherson extract prepared in Example 2, a disk diffusion method was performed as follows.

Dilute S. pyogenes, S. aureus, and methicillin resistant Staphylococcus aureus grown in liquid medium overnight to 1 / 1,000. , 100 μl each of which was spread well spread on agar medium. 5 μl of a round filter paper was dissolved in 5 μl of a solution dissolved in ethanol such that the concentration of the extracts or fractions prepared in Examples 1 and 2 was 25 mg / ml. . After incubating at 37 ° C. or 30 ° C. for 24 hours or 48 hours, the antibacterial activity was measured by measuring the bacterial growth inhibited part (clear zone, clear zone), and the results are shown in Table 1 and FIG. 1. Meanwhile, conventional antibiotics methicillin (Methicillin) and penicillin (Penicillin) as a control group.

Strain Example 1 Example 2 Methicillin penicillin Streptococcus pyogenes ++++ +++++ ++++ ++++ Staphylococcus aureus ++++ ++++ ++++ ++++ MRSA +++ +++ - +

(No inhibitory effect:-, 7-20 mm: +, 21-40 mm: ++, 41-60 mm: +++, 61-80 mm: ++++, bacterial absence: +++++)

As shown in Table 1 and Figure 1, the Buddha extract or fractions thereof prepared in the present invention exhibited a large clear zone to confirm that the antimicrobial activity is very good, and also showed a high antimicrobial activity against MRSA.

[ Experimental Example  2] toxicity test

Animal experiments were performed to test the toxicity of the Buddha extract or fractions thereof prepared in the present invention. 17-23 g of healthy, previously unused albino mice were used. The test animals were divided into six test groups and three control groups, each of three animals, and 20 mg / kg, 10 mg / kg, and 1 mg / kg, respectively, of the Busonson extract prepared in the present invention were injected into the test groups 1 to 3, respectively. , 4 to 6 test groups were injected with a fraction of the Buddha extract prepared in the present invention by 20 mg / kg, 10 mg / kg, 1 mg / kg, respectively. Meanwhile, physiological saline was injected into the three control groups by 20 mg / kg, 10 mg / kg and 1 mg / kg, respectively. Immediately after administration, body weights and signs of biological abnormalities were visually observed 4 hours, 24 hours, 48 hours, and 72 hours, and the results are shown in Table 2. As shown in Table 2, there were no signs of biological abnormality and no individual died during the observation period. Therefore, it was confirmed that the Buddha extract or a fraction thereof is a safe drug.

Life and death Abnormal symptoms / weight change survival Dead Immediately 24 hours 48 hours 72 hours
Test group One ○ none none none none 2 ○ none none none none 3 ○ none none none none 4 ○ none none none none 5 ○ none none none none 6 ○ none none none none
Control group One ○ none none none none 2 ○ none none none none 3 ○ none none none none

In the following, the preparation examples of the pharmaceutical composition of the present invention comprising the butcherson extract or a fraction thereof as an active ingredient, but the scope of the present invention is not limited by the following preparation examples.

[Example 1]

Manufacture of tablets

Table 3 shows an example of the preparation according to an embodiment of the present invention, the formulation of the tablet form.

ingredient content Buddha hand extract of Example 1 or fraction of Example 2 10 mg Lactose 100 mg Starch 100 mg Talc 2 mg Magnesium stearate 2 mg

The tablets are prepared by mixing the components and then tableting according to a conventional method for preparing tablets.

[Example 2]

Preparation of capsules

Table 4 shows a preparation example according to one embodiment of the present invention, a capsule form.

ingredient content Buddha hand extract of Example 1 or fraction of Example 2 20 mg Lactose 50 mg Starch 50 mg Talc 5mg Magnesium stearate Suitable amount

According to a conventional capsule manufacturing method, the above ingredients are mixed and filled into gelatin capsules to prepare capsules.

[Example 3]

Injection preparation

Table 5 shows a preparation example according to an embodiment of the present invention, in the form of an injection.

ingredient content Buddha hand extract of Example 1 or fraction of Example 2 10 mg Mannitol 150mg Sterile sterilized water for injection 2800 mg Na ₂ HPO _{4 12} H ₂ 0 24mg

According to the conventional method for preparing an injection, the amount of the above-mentioned ingredient per one ampoule (2 ml) is prepared.

The present invention may be embodied in many other specific forms without departing from the spirit or essential characteristics of the invention.

Claims (6)

Budsonson extract or fractions thereof; And
A pharmaceutical composition for the prevention or treatment of tonsillitis, characterized in that it comprises a pharmaceutically acceptable carrier.
According to claim 1, wherein the Buddha hand extract,
A pharmaceutical composition for preventing or treating tonsillitis, characterized in that the extraction using water, C1 to C4 lower alcohol or a mixed solvent thereof.
According to claim 2, wherein the lower alcohol of C1 to C4,
Methanol or ethanol, characterized in that tonsillitis prevention or treatment pharmaceutical composition.
The method of claim 1, wherein the fraction,
The Buddha extract is fractionated using an organic solvent, tonsillitis prevention or treatment pharmaceutical composition.
The method of claim 4, wherein the organic solvent,
Hexane, chloroform, methylene chloride, ethyl acetate or butanol, characterized in that tonsillitis prevention or treatment pharmaceutical composition.
The method of claim 1, wherein the pharmaceutical composition,
To the total weight of the pharmaceutical composition characterized in that it comprises 0.02 ~ 50% by weight of the Buddha extract or the fraction of the Buddha extract, tonsillitis prevention or treatment pharmaceutical composition.

Images